JP2022512713A5 - - Google Patents

Info

Publication number
JP2022512713A5
JP2022512713A5 JP2021520958A JP2021520958A JP2022512713A5 JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5 JP 2021520958 A JP2021520958 A JP 2021520958A JP 2021520958 A JP2021520958 A JP 2021520958A JP 2022512713 A5 JP2022512713 A5 JP 2022512713A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520958A
Other languages
English (en)
Japanese (ja)
Other versions
JP7518821B2 (ja
JP2022512713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/078093 external-priority patent/WO2020079086A1/en
Publication of JP2022512713A publication Critical patent/JP2022512713A/ja
Publication of JP2022512713A5 publication Critical patent/JP2022512713A5/ja
Priority to JP2024108735A priority Critical patent/JP2024138363A/ja
Application granted granted Critical
Publication of JP7518821B2 publication Critical patent/JP7518821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520958A 2018-10-16 2019-10-16 重症筋無力症の治療方法 Active JP7518821B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024108735A JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16
US62/746,174 2018-10-16
PCT/EP2019/078093 WO2020079086A1 (en) 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024108735A Division JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Publications (3)

Publication Number Publication Date
JP2022512713A JP2022512713A (ja) 2022-02-07
JP2022512713A5 true JP2022512713A5 (cg-RX-API-DMAC7.html) 2022-10-24
JP7518821B2 JP7518821B2 (ja) 2024-07-18

Family

ID=68290236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520958A Active JP7518821B2 (ja) 2018-10-16 2019-10-16 重症筋無力症の治療方法
JP2024108735A Pending JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024108735A Pending JP2024138363A (ja) 2018-10-16 2024-07-05 重症筋無力症の治療方法

Country Status (14)

Country Link
US (1) US20220144941A1 (cg-RX-API-DMAC7.html)
EP (1) EP3866933A1 (cg-RX-API-DMAC7.html)
JP (2) JP7518821B2 (cg-RX-API-DMAC7.html)
KR (2) KR102916165B1 (cg-RX-API-DMAC7.html)
CN (1) CN113646051A (cg-RX-API-DMAC7.html)
AR (1) AR117653A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019361247B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007092A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116091A1 (cg-RX-API-DMAC7.html)
IL (1) IL282137A (cg-RX-API-DMAC7.html)
MA (1) MA53903A (cg-RX-API-DMAC7.html)
MX (1) MX2021004351A (cg-RX-API-DMAC7.html)
SG (1) SG11202103801UA (cg-RX-API-DMAC7.html)
WO (1) WO2020079086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
CA3200972A1 (en) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法
MX2023012032A (es) * 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
EP4519683A1 (en) * 2022-05-05 2025-03-12 UCB Biopharma SRL Treatment of myasthenia gravis with zilucoplan
JP2025519559A (ja) * 2022-06-11 2025-06-26 インヒブルクス バイオサイエンシズ インコーポレイテッド FcRn結合ポリペプチド及びその使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008538919A (ja) 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー FcRn抗体およびその使用
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
EP2453823B1 (en) 2009-07-14 2015-05-13 WaveTec Vision Systems, Inc. Ophthalmic surgery measurement system
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée

Similar Documents

Publication Publication Date Title
JP2021522801A5 (cg-RX-API-DMAC7.html)
JP2020002171A5 (cg-RX-API-DMAC7.html)
JP2020002172A5 (cg-RX-API-DMAC7.html)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
Kolesnik et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication
JP2021191267A5 (cg-RX-API-DMAC7.html)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
JP2019513726A5 (cg-RX-API-DMAC7.html)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2009518441A5 (cg-RX-API-DMAC7.html)
JP2017503820A5 (cg-RX-API-DMAC7.html)
JP2021510523A5 (cg-RX-API-DMAC7.html)
JP2004510752A5 (cg-RX-API-DMAC7.html)
JP2019505527A5 (cg-RX-API-DMAC7.html)
JP2022517441A (ja) Btla抗体
TWI866304B (zh) 抗EphA4抗體
JP2012524071A5 (cg-RX-API-DMAC7.html)
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
JP2009502139A5 (cg-RX-API-DMAC7.html)
JP2018526330A5 (cg-RX-API-DMAC7.html)
JP2023089191A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2017529324A5 (cg-RX-API-DMAC7.html)